Literature DB >> 9542520

Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma.

R Pichlmayr1, A Weimann, K J Oldhafer, H J Schlitt, G Tusch, R Raab.   

Abstract

The enthusiasm to treat or even cure patients with unresectable hepatobiliary malignancy by total hepatectomy and liver transplantation has considerably diminished. Nowadays, due to organ-donor shortage, patients have to be selected with predictable likelihood for long-term survival. According to own experience and a review of the literature, liver transplantation may be considered in unresectable early stage hepatocellular and proximal bile duct carcinoma, the uncommon entities fibrolamellar carcinoma, epithelioid haemangioendothelioma and hepatoblastoma as well as in liver metastases from neuroendocrine tumours. At present, advanced stages of hepatocellular and proximal bile duct carcinoma, as well as intrahepatic bile duct carcinoma, haemangiosarcoma and metastases from nonendocrine tumours, should be excluded from transplantation. In order to cure the cancer-bearing disease, liver transplantation might be the ideal treatment for small but still resectable hepatocellular carcinoma with underlying cirrhosis. Our retrospective comparison of survival after resection and transplantation for early stage hepatocellular carcinoma does not reveal a significant difference. Although a tendency has been observed in favour of transplantation, resection of these tumours is still justifiable, not least because of donor organ shortage.

Entities:  

Mesh:

Year:  1998        PMID: 9542520     DOI: 10.1016/s0748-7983(98)80130-3

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

Review 1.  Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations.

Authors:  Clarence Nicholas Kotewall; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-08

Review 2.  Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature.

Authors:  Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy.

Authors:  Zhuo Shao; Rocio Lopez; Bo Shen; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

5.  Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.

Authors:  Ronnie Tung-Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

6.  Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis.

Authors:  Hong-Yu Li; Yong-Gang Wei; Lv-Nan Yan; Bo Li
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

Review 7.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

8.  Resection prior to liver transplantation for hepatocellular carcinoma.

Authors:  Jacques Belghiti; Alexandre Cortes; Eddie K Abdalla; Jean-Marc Régimbeau; Kurumboor Prakash; François Durand; Daniele Sommacale; Federica Dondero; Mickael Lesurtel; Alain Sauvanet; Olivier Farges; Reza Kianmanesh
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

9.  Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?

Authors:  René Adam; Daniel Azoulay; Denis Castaing; Rony Eshkenazy; Gérard Pascal; Kentaro Hashizume; Didier Samuel; Henri Bismuth
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

10.  Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.

Authors:  Torsten Voigtländer; Jochen Metzger; Holger Husi; Martha M Kirstein; Martin Pejchinovski; Agnieszka Latosinska; Maria Frantzi; William Mullen; Thorsten Book; Harald Mischak; Michael P Manns
Journal:  J Biomed Sci       Date:  2020-01-03       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.